BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
BIOMARIN PHARMACEUTICAL INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$54.67−0.01 (-0.02%)
Close on Oct 19, 2026
- Market cap
- $10.63B
- P/E (TTM)
- 143.9
- Dividend yield
- –
BIOMARIN PHARMACEUTICAL INC revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product revenues | $3.36B | $3.19B | $3.17B | $3.04B | $3.02B | $2.91B | $2.81B | $2.71B | $2.54B | $2.42B | $2.37B | $2.26B | 98.8% | +11.5% |
| VOXZOGO | $964.19M | $933.05M | $926.92M | $862.03M | $833.43M | $795.96M | $735.09M | $672.33M | $605.52M | $534.93M | $469.88M | $390.95M | 28.3% | +15.7% |
| VIMIZIM | $792.86M | $813.91M | $792.05M | $777.62M | $773.02M | $735.61M | $739.78M | $724.29M | $705.01M | $704.38M | $701.05M | $677.46M | 23.3% | +2.6% |
| NAGLAZYME | $507.57M | $501.18M | $485.40M | $475.18M | $485.06M | $488.25M | $479.58M | $467.84M | $444.85M | $402.90M | $420.29M | $422.51M | 14.9% | +4.6% |
| PALYNZIQ | $458.83M | $429.60M | $433.31M | $408.40M | $390.25M | $372.61M | $355.05M | $342.45M | $330.70M | $317.28M | $303.92M | $288.40M | 13.5% | +17.6% |
| BRINEURA | $195.82M | $193.14M | $186.40M | $184.73M | $173.78M | $170.40M | $169.08M | $165.01M | $169.04M | $161.79M | $161.89M | $160.89M | 5.7% | +12.7% |
| ALDURAZYME | $183.38M | $196.27M | $208.51M | $198.16M | $215.48M | $197.60M | $183.89M | $187.56M | $130.35M | $132.11M | $131.25M | $126.20M | 5.4% | -14.9% |
| KUVAN | $95.68M | $98.27M | $99.53M | $104.52M | $108.61M | $110.13M | $120.90M | $129.30M | $144.13M | $166.20M | $180.77M | $197.65M | 2.8% | -11.9% |
| Royalty and other revenues | $42.01M | $49.12M | $53.49M | $49.93M | $46.48M | $43.95M | $44.47M | $45.85M | $47.04M | $47.72M | $46.69M | $45.68M | 1.2% | -9.6% |
| ROCTAVIAN | $30.28M | $27.77M | $35.64M | $33.44M | $37.49M | $35.73M | $26.07M | $18.18M | $11.77M | $4.34M | $3.49M | $822.00K | 0.9% | -19.2% |
| Total enzyme product revenues | – | – | – | – | – | – | – | – | – | – | $1.72B | $1.68B | – | – |
By region
From the segment and revenue-disaggregation notes of Biomarin Pharmaceutical's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.